NSAID gastropathy: A new understanding

Archives of Internal Medicine

Volumn 156, Issue 15, 1996, Pages 1623-1628

  Roth, Sanford H ^a  

^a Arthritis Center Ltd   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DICLOFENAC; ETODOLAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OXAPROZIN; PIROXICAM; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; REBAMIPIDE; SALICYLIC ACID DERIVATIVE; SULINDAC;

CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG FORMULATION; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STOMACH DISEASE; STOMACH PROTECTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL HEMORRHAGE; HUMANS; PEPTIC ULCER; RISK; STOMACH DISEASES;

EID: 0029838240     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.15.1623     Document Type: Review

References (82)

1. Roth SH. Salicylates revisited: are they still the hallmark of anti-inflammatory therapy? Drugs. 1988;36:1-6.
2. Roth SH. Prevention of NSAID-induced gastric mucosal damage and gastric ulcer: a review of clinical studies. J Drug Dev. 1989;1:255-263.
3. Wilcox CM, Shalek KA, Cotsonis G. Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch Intern Med. 1994; 154:42-46.
4. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy: we started it - can we stop it? Arch Intern Med. 1986;146:1075-1076.
5. Roth SH, Bennett RE, Mitchell CS, Hartman RJ. Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy: double-blind long-term evaluation. Arch Intern Med. 1987;147:1798-1801.
6. Carson JL, Strom BL, Super KA, West SL, Morse ML The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med. 1987;147:85-88.
7. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991;114:257-263.
8. Graham DY, Smith JL. Aspirin and the stomach. Ann Intern Med. 1986;4:390-398.
9. Roth SH. From peptic ulcer disease to NSAID gastropathy: an evolving nosology. Drugs Aging. 1995;6:358-367.
10. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987;28:527-532.
11. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology. 1989;96:647-655.
12. Langman MJS. Ulcer complications and nonsteroidal anti-inflammatory drugs. Am J Med. 1988; 84(suppl 2A):15-18.
13. Bloom BS. Risk and cost of gastrointestinal side effects associated with non-steroidal anti-inflammatory drugs. Arch Intern Med. 1989:49: 1019-1022.
14. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med. 1988;84(suppl 2A):20-24.
15. Richardson CT. Peptic ulcer: pathogenesis. In: Wyngaarden JB, Smith LT Jr, eds. Textbook of Medicine. Philadelphia, Pa: WB Saunders Co: 1988: 692-695.
16. Szabo S, Goldberg I. Experimental pathogenesis: drugs and chemical lesions in the gastric mucosa. Scand J Gastroenterol. 1990;25(suppl 174):1-8.
17. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy: recognition and response. Arch Intern Med. 1987;147:2093-2100.
18. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract: the double-edged sword. Arthritis Rheum. 1995;38:5-18.
19. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 1971;231:232-235.
20. Schoen RT, Vender RJ. Mechanisms of nonsteroidal antiinflammatory drug-induced gastric damage. Am J Med. 1989;86:449-458.
21. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1994;271:927-934.
22. Morgan DW. Recent advances in eicosanoid biosynthesis inhibitors of prostaglandin endoperoxide synthase, phospholipase a2 and arachidonic acid release. Exp Opin Invest Drugs. 1994;3:1063-1065.
23. Dewitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci U S A. 1988;85:1412-1416.
24. Hla T, Neilson K. Human cyctooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992;89:7384-7388.
25. Sun DC, Roth SH, Mitchell CS, Englund DW. Upper gastrointestinal disease in rheumatoid arthritis. Am J Dig Dis Soi. 1974;19:405-410.
26. Roth SH, Agrawal N, Mahowald M, et al. Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Meet. 1989;149:775-779.
27. Walt R, Katschinski B, Logan R, Ashley J, Langman M. Rising frequency of ulcer perforation in elderly patients in the United Kingdom. Lancet. 1986;1:489-492.
28. Fries JF, Williams KA, Bloch D, et al. Nonsteroidal anti-inflammatory drug associated gastropatny: incidence and risk factor models. Am J Med. 1991;91:213-222.
29. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use in peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735-740.
30. Garcla-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation with individual nonsteroidal anti-inflammatory drugs. Lancet. 1994;343:769-772.
31. Rees Willett L, Carson JL, Strom BL. Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs. Drug Safety. 1994;10:170-181.
32. Janssen M, Dijkmans BAC, Lamers CBHW, Zwinderman AH, Vandenbroucke JP. A gastroscopic study of the predictive value of risk factors for nonsteroidal anti-inflammatory drug-associated ulcer disease in rheumatoid arthritis patients. Br J Rheumatol. 1994;33:449-454.
33. Kim JG, Graham DY, Misoprostol Study Group. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. Am J Gastroenterol. 1994;89:203-207.
34. Thillainayagam AV, Tabaqchali S, Warrington SJ, Farthing MJG. Interrelationships between Helicobacter pylori infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease: a prospective study in healthy volunteers. Dig Dis Sci. 1994;39:1085-1089.
35. Laine L, Cominelli F, Sloane R, Casini-Raggi V, Marin-Sorensen M, Weinstein WM. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial. Aliment Pharmacol Ther. 1995;9:127-135.
36. Hayllar J, Macpherson A, Bjarnason I. Gastroprotection and nonsteroidal anti-inflammatory drugs (NSAIDs): rationale and clinical implications. Drug Safety. 1992;7:86-105.
37. Lanza FL, Graham DY, Davis RE, Rack MF. Endoscopic evaluation of cimetidine and sucralfate for prevention of naproxen-induced gastroduodenal injury: effect of scoring method. Dig Dis Sci. 1990;35:1494-1499.
38. Graham DY, Agrawal NM, Roth SH. Prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet. 1988;2:1277-1280.
39. Kurata JH, Abbey DE. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol. 1990;12:260-266.
40. Paulus HE. FDA arthritis advisory committee meeting: post-marketing surveillance of nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1985; 28:1168-1169.
41. Committee for Safety of Medications. CSM update: nonsteroidai anti-inflammatory drugs and serious gastrointestinal adverse reactions, 2. BMJ. 1986;292:1190-1193.
42. Lipani JA, Poland M. Clinical update of the efficacy and relative safety of nabumetone in long term clinical trials, Inflammopharmacology. 1995;3:351-361.
43. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenteroiogy. 1993;105:1078-1088.
44. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual nonsteroidal anti-inflammatory drugs. Lancet. 1994;343:1075-1078.
45. Jeremy JY, Mikhailidis DP. Barradas MA, Kirk RM, Dandona P. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function. Br J Rheumatol. 1990;29:116-119.
46. Blower PR. The unique pharmacologie profile of nabumetone. J Rheumatol. 1992;19(suppl 36):13-19.
47. Melarange R, Sentry C, Moore G, et al. One month repeat oral dosing of nabumetone, in contrast with diclofenac, does not alter gastrointestinal mucosal integrity in the rat Arthritis Rheum. 1992; 35(suppl):342. Abstract.
48. Melarange R, Blower P, Spangler R. Comparison of the anti-inflammatory activity and gastrointestinal irritancy of nabumetone, ibuprofen, and diclofenac in rats following chronic administration. Eur J Rheumatol Inflamm. 1994;14:23-27.
49. Melarange R, Gentry C, Blower PR. Nabumetone, an effective anti-inflammatory agent, lacks gastrointestinal irritancy in the rat when dosed orally for one month: comparison with tiaprofenic acid and etodolac. Eur J Rheumatol Inflamm. 1994;14:15-22.
50. Melarange R, Gentry C, Durie M. Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat: differentiation of effects between nabumetone and etodolac. Dig Dis Sci. 1994;39:601-608.
51. Melarange R, Gentry C, Blower PR, et al. Nabumetone, in contrast to etodolac, lacks gastrointestinal irritancy in the rat: assessment by the inflammatory marker, haptoglobin, and blood loss. Inflammopharmacology. 1995;3:259-270.
52. Roth SH. Upper gastrointestinal safety with nabumetone. J Rheumatol. 1992;19(suppl 36):74-79.
53. Roth SH, Bennett RE, Caldron P, et al. A long-term endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. J Rheumatol. 1994;21:1118-1123.
54. Bianchi Porro G, Montrone F, Petrillo M. Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. Am J Gastroenterol. 1995;90:1485-1488.
55. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med. 1993;153:2565-2571.
56. Bloom BS, Lipani J, Schainbaum S, et al. Cost-effectiveness analysis of preventing perforation, ulcers and bleeds associated with nonsteroidal anti-inflammatory drugs. Arthritis Rheum. 1994; 37(suppl):248. Abstract.
57. Bentkover JE, Baker AM, Kaplan H. Nabumetone in elderty patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol Pharmacoeconomics. 1994;5:335-342.
58. Bacon P. Worldwide experience with etodolac (Lodine) 300 mg b.i.d, in the treatment of osteoarthritis. Rheumatol Int. 1993;13(suppl):7-12,
59. Schattenkirchner M. The safety profile of sustained-release etodolac. Rheumatol Int. 1993;13(suppl): S31-S35.
60. Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm. 1990;10:56-65.
61. Lanas A, Sakar MC, Kirschowitz BI. Objective test-ing reveals a very strong association of acetyl salicylic acid with upper and lower gastrointestinal bleeding. Gastroenterology. 1991;100:106. Abstract.
62. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med. 1992;327:749-754.
63. McCarthy DM. Nonsteroidal antiinflammatory druginduced ulcers: management by traditional therapies. Gastroenterology. 1989;96:662-674.
64. Roth SH. Efficacy of antacid therapy for NSAID-induced symptomatic gastropathy. Pract Gastroenterol. 1994;18:14-20.
65. Bijlsma JWJ. Treatment of NSAID-induced gastrointestinal lesions with cimetidine: an international multicentre collaborative study. Aliment Pharmacol Ther. 1988;2(suppl):85-96.
66. Croker JR, Cotton PB, Boyle AC, Kinsella P. Cimetidine for peptic ulcer in patients with arthritis. Ann Rheum Dis. 1980;39:275-278.
67. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. NSAID-induced gastroduodenal damage: effect of ranitidine prophylaxis. Gastroenterology. 1988;94:A111. Abstract
68. Taha AS, Hudson N, Tyre P, et al. Prevention of NSAID-related gastric and duodenal ulcers by famotidine: a placebo-controlled double-blind study. Gastroenterology. 1994:106(suppl):A190. Abstract.
69. Bianchi-Porro G, Santalucia F, Petrillo M, Montrone F, Caruso I. Omeprazole vs placebo in the prevention of NSAIDs-induced gastroduodenal lesions. Gastroenterology. 1994;106:A51. Abstract.
70. Walan A, Bader JP, Classen M, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med. 1989;320:69-75.
71. Levenson SD, Koch J, Cello JP. Omeprazole prophylaxis of acute non-steroidal anti-inflammatory drug associated gastric and duodenal injury. Gastrointest Endosc. 1994;40:P86. Abstract.
72. Scheiman JM, Behler EM, Loeffler KM, Elta GH. Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci. 1994;39:97-103.
73. Bolten W, Brodenfeldt R. Efficacy of misoprostoi in the therapy of NSAID-induced symptoms and lesions of the upper Gl tract under continued NSAID medication. Clin Exp Rheumatol. 1990; 8(suppl 4):59. Abstract.
74. Gels GS, Steid H. Prevention of diclofenac induced gastroduodenal mucosal damage by Cytotec. Clin Exp Rheumatol. 1990:8(suppl 4):58. Abstract.
75. Silverstein FE, Geis GS, Struthers BJ, MUCOSA Study Group. NSAIDs and gastrointestinal injury: clinical outcome, the MUCOSA Trial. Gastroenterology. 1994;106:A180. Abstract.
76. Graham DY, Smith JL, Dobbs SM. Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci. 1988;28:1-6.
77. Edelson JT, Tosteson ANA. Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA. 1990;264:41-47.
78. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med. 1989;149:2061-2065.
79. Knill-Jones R, Drummond M, Kohli H, Davies L. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving nonsteroidal anti-inflammatory drugs. Postgrad Med J. 1990;66:639-646.
80. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal anti-inflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum. 1993;36:447-459.
81. Stucki G, Johannesson M, Liang MH. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? Arch Intern Med. 1994;154:2020-2025,
82. Nanakawa K. Clinical investigation of rebamipide against gastric mucosal injury induced by nonsteroidal anti-inflammatory drugs (NSAIDs). J Adult Dis. 1993;23:1477-1487.